Hypoparathyroidism
Hypoparathyroidism is a disease characterized by inadequately low circulating concentrations of parathyroid hormone (PTH) resulting in low calcium levels and increased phosphate levels in the blood. Symptoms of the disease result from increased neuromuscular irritability caused by hypocalcaemia and...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature
2017
|
| _version_ | 1797092320677462016 |
|---|---|
| author | Mannstadt, M Bilezikian, JP Thakker, RV Hannan, FM Clarke, BL Rejnmark, L Mitchell, DM Vokes, TJ Winer, KK Shoback, DM |
| author_facet | Mannstadt, M Bilezikian, JP Thakker, RV Hannan, FM Clarke, BL Rejnmark, L Mitchell, DM Vokes, TJ Winer, KK Shoback, DM |
| author_sort | Mannstadt, M |
| collection | OXFORD |
| description | Hypoparathyroidism is a disease characterized by inadequately low circulating concentrations of parathyroid hormone (PTH) resulting in low calcium levels and increased phosphate levels in the blood. Symptoms of the disease result from increased neuromuscular irritability caused by hypocalcaemia and include tingling, muscle cramps and seizures. The most common cause of the disease is inadvertent removal of, or injury to, the parathyroid glands during neck surgery, followed by genetic, idiopathic and autoimmune aetiologies. Conventional treatment includes activated vitamin D and/or calcium supplements, but this treatment does not fully replace the functions of PTH and can lead to short-term problems (such as hypocalcaemia, hypercalcaemia and increased urinary calcium excretion) and long-term complications (which include nephrocalcinosis, kidney stones and brain calcifications). PTH replacement has emerged as a new treatment option. Clinical trials using human PTH(1–34) and PTH(1–84) showed that this treatment was safe and effective in studies lasting up to 6 years. Recombinant human PTH(1–84) has been approved in the United States and Europe for the management of hypoparathyroidism; however, its effect on long-term complications is still being evaluated. Clinical practice guidelines, which describe the consensus of experts in the field, have been published and recognize the need for more research to optimize care. In this Primer, we summarize current knowledge of the prevalence, pathophysiology, clinical presentation and management of hypoparathyroidism. |
| first_indexed | 2024-03-07T03:44:27Z |
| format | Journal article |
| id | oxford-uuid:bef9cbc5-52e8-4b74-99a6-7312d7a9922b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:44:27Z |
| publishDate | 2017 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:bef9cbc5-52e8-4b74-99a6-7312d7a9922b2022-03-27T05:44:07ZHypoparathyroidismJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bef9cbc5-52e8-4b74-99a6-7312d7a9922bEnglishSymplectic ElementsSpringer Nature2017Mannstadt, MBilezikian, JPThakker, RVHannan, FMClarke, BLRejnmark, LMitchell, DMVokes, TJWiner, KKShoback, DMHypoparathyroidism is a disease characterized by inadequately low circulating concentrations of parathyroid hormone (PTH) resulting in low calcium levels and increased phosphate levels in the blood. Symptoms of the disease result from increased neuromuscular irritability caused by hypocalcaemia and include tingling, muscle cramps and seizures. The most common cause of the disease is inadvertent removal of, or injury to, the parathyroid glands during neck surgery, followed by genetic, idiopathic and autoimmune aetiologies. Conventional treatment includes activated vitamin D and/or calcium supplements, but this treatment does not fully replace the functions of PTH and can lead to short-term problems (such as hypocalcaemia, hypercalcaemia and increased urinary calcium excretion) and long-term complications (which include nephrocalcinosis, kidney stones and brain calcifications). PTH replacement has emerged as a new treatment option. Clinical trials using human PTH(1–34) and PTH(1–84) showed that this treatment was safe and effective in studies lasting up to 6 years. Recombinant human PTH(1–84) has been approved in the United States and Europe for the management of hypoparathyroidism; however, its effect on long-term complications is still being evaluated. Clinical practice guidelines, which describe the consensus of experts in the field, have been published and recognize the need for more research to optimize care. In this Primer, we summarize current knowledge of the prevalence, pathophysiology, clinical presentation and management of hypoparathyroidism. |
| spellingShingle | Mannstadt, M Bilezikian, JP Thakker, RV Hannan, FM Clarke, BL Rejnmark, L Mitchell, DM Vokes, TJ Winer, KK Shoback, DM Hypoparathyroidism |
| title | Hypoparathyroidism |
| title_full | Hypoparathyroidism |
| title_fullStr | Hypoparathyroidism |
| title_full_unstemmed | Hypoparathyroidism |
| title_short | Hypoparathyroidism |
| title_sort | hypoparathyroidism |
| work_keys_str_mv | AT mannstadtm hypoparathyroidism AT bilezikianjp hypoparathyroidism AT thakkerrv hypoparathyroidism AT hannanfm hypoparathyroidism AT clarkebl hypoparathyroidism AT rejnmarkl hypoparathyroidism AT mitchelldm hypoparathyroidism AT vokestj hypoparathyroidism AT winerkk hypoparathyroidism AT shobackdm hypoparathyroidism |